Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.

doi:10.1182/blood-2015-11-683334

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.

Blood - 7 Jul 2016

McKerrell Thomas, Moreno Thaidy, Ponstingl Hannes, Bolli Niccolo, Dias João M L, Tischler German, Colonna Vincenza, Manasse Bridget, Bench Anthony, Bloxham David, Herman Bram, Fletcher Danielle, Park Naomi, Quail Michael A, Manes Nicla, Hodkinson Clare, Baxter Joanna, Sierra Jorge, Foukaneli Theodora, Warren Alan J, Chi Jianxiang, Costeas Paul, Rad Roland, Huntly Brian, Grove Carolyn, Ning Zemin, Tyler-Smith Chris, Varela Ignacio, Scott Mike, Nomdedeu Josep, Mustonen Ville, Vassiliou George S

Abstract excerpt

The diagnosis of hematologic malignancies relies on multidisciplinary workflows involving morphology, flow cytometry, cytogenetic, and molecular genetic analyses. Advances in cancer genomics have identified numerous recurrent mutations with clear prognostic and/or therapeutic significance to different cancers. In myeloid malignancies, there is a clinical imperative to test for such mutations in mainstream...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to DNA (Cytosine-5-)-Methyltransferases

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to DNA Methyltransferase 3A

Share to Formins

Share to Hematologic Neoplasms

Share to Histone-Lysine N-Methyltransferase

Share to Leukemia, Myeloid

Share to Myeloid-Lymphoid Leukemia Protein

Share to Oncogene Proteins, Fusion

Source

Open in PubMed Open full text

Identifiers

PMID: 27121471
DOI: 10.1182/blood-2015-11-683334
PMCID: PMC4937362

Genes

DIAPH2
FLT3

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-07.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Development and validation of a comprehensive genomic diagnostic tool for myeloid malignancies.PMID 27121471Read ↗

Comprehensive genetic diagnosis of acute myeloid leukemia by next-generation sequencing.Semantic proximity Read ↗

Genomic profiling for clinical decision making in myeloid neoplasms and acute leukemia.Semantic proximity Read ↗

Molecular findings in myeloid neoplasms.Semantic proximity Read ↗

Clinical characterization of the mutational landscape of 24,639 real-world samples from patients with myeloid malignancies.Semantic proximity Read ↗

Clinical Validation of a Myeloid Next-Generation Sequencing Panel for Single-Nucleotide Variants, Insertions/Deletions, and Fusion Genes.Semantic proximity Read ↗

Molecular Diagnostic Testing for Hematopoietic Neoplasms: Linking Pathogenic Drivers to Personalized Diagnosis.Semantic proximity Read ↗

Analytical validation and performance characteristics of a 48-gene next-generation sequencing panel for detecting potentially actionable genomic alterations in myeloid neoplasmsSemantic proximity Read ↗

Integrated genomic DNA/RNA profiling of hematologic malignancies in the clinical setting.Semantic proximity Read ↗

Clinical Significance of DNA Variants in Chronic Myeloid Neoplasms: A Report of the Association for Molecular Pathology.Semantic proximity Read ↗

Targeted next generation sequencing can serve as an alternative to conventional tests in myeloid neoplasmsSemantic proximity Read ↗

Molecular diagnosis of acute myeloid leukemia.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.